§ 01

Overview: Opioids and myofascial pain

Opioids — including morphine, oxycodone, hydrocodone, fentanyl, tramadol, and codeine — are powerful analgesic medications that bind to mu, kappa, and delta opioid receptors in the central nervous system. They activate descending pain inhibitory pathways and modulate the affective experience of pain. Opioids are highly effective for acute surgical pain, severe trauma, and cancer-related pain, and they remain indispensable medications in those specific clinical contexts.

However, for myofascial trigger point pain, opioids are fundamentally the wrong tool. They do not address the peripheral mechanical pathology that defines trigger points — the contracted sarcomeres, the dysfunctional motor endplates, the local energy crisis, or the sensitizing biochemical milieu. Instead, they temporarily suppress the brain’s registration of the pain signal while the structural source of pain persists unchanged.

Opioids may mask myofascial pain without addressing the underlying trigger points, potentially delaying effective treatment.

Major medical guidelines have converged on this conclusion. The CDC Clinical Practice Guideline (2022), the VA/DoD Clinical Practice Guideline (2022), the American Academy of Pain Medicine (AAPM), and the American Pain Society (APS) all specifically recommend against opioids for chronic musculoskeletal pain, including myofascial pain syndrome.

§ 02

Why Opioids Fail for Trigger Points

There are seven fundamental reasons why opioids are ineffective and counterproductive for myofascial trigger point pain.

§ 03

The Pharmacology of Why

Opioid analgesia comes entirely from central receptor activation — none of these mechanisms touch the peripheral motor endplate that drives a trigger point.

Mu Receptor Agonism

Opioids bind primarily to mu-opioid receptors (MOR) in the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), dorsal horn of the spinal cord, and limbic system. This provides analgesia by activating descending inhibitory pathways and modulating the affective component of pain. However, mu-receptor activation has no effect on the motor endplate, the acetylcholine release that drives taut band formation, the sarcomere contracture, or the local ischemia within the trigger point. The pain signal from the trigger point continues to fire — the opioid simply reduces the brain's registration of that signal.

Descending Inhibition Enhancement

Opioids activate the descending pain modulation system — specifically, they disinhibit PAG neurons by suppressing inhibitory GABAergic interneurons. This releases serotonergic and noradrenergic projections from the RVM and locus coeruleus that inhibit nociceptive transmission in the dorsal horn. While this temporarily reduces the perceived intensity of trigger point pain, the trigger point itself continues to fire spontaneous electrical activity (spontaneous endplate noise), maintain its biochemical milieu of sensitizing substances, and perpetuate the taut band. When the opioid effect wanes, full pain perception returns.

Rapid Tolerance Development

Pharmacological tolerance to opioid analgesia develops within 1 to 4 weeks of regular use through multiple mechanisms: receptor desensitization (phosphorylation of mu-receptors by G-protein-coupled receptor kinases), receptor internalization and downregulation, uncoupling of G-proteins from receptor signaling, and upregulation of the cAMP-adenylyl cyclase pathway. Tolerance necessitates dose escalation to maintain the same level of pain suppression, progressively increasing the risk of side effects, dependence, and overdose — all for a medication that is not treating the underlying condition.

Physical Dependence

Physical dependence — the development of withdrawal symptoms upon abrupt discontinuation — can begin after as few as 5 to 7 days of continuous opioid use. Withdrawal symptoms include severe myalgias, arthralgia, insomnia, diaphoresis, piloerection, abdominal cramping, diarrhea, anxiety, and irritability. Ironically, opioid withdrawal causes diffuse myalgias (muscle pain) that can worsen the perception of existing trigger point pain and is often misinterpreted as a sign that the opioids were "working" and need to be continued.

Endogenous Opioid Downregulation

Exogenous opioid administration suppresses the body's production and release of endogenous opioid peptides — beta-endorphin, enkephalins, and dynorphins. With chronic use, the hypothalamic-pituitary axis reduces beta-endorphin output, and opioid receptor density in key pain-modulating regions decreases. This means the patient loses their own natural pain-modulating capacity, becoming more dependent on exogenous opioids for baseline pain tolerance. When the exogenous opioid is removed, the patient has less natural pain modulation than they had before treatment began.

§ 04

The Opioid Crisis Connection

The prescribing of opioids for chronic musculoskeletal pain — including myofascial pain syndrome — has been a significant driver of the opioid epidemic. Chronic non-cancer pain accounts for the vast majority of opioid prescriptions dispensed in the United States. Myofascial pain syndrome is one of the most prevalent chronic pain conditions, with estimates suggesting that a substantial proportion of patients presenting to specialized pain clinics have myofascial trigger points as a primary or contributing source of their pain.

The routine prescribing of opioids for these patients has contributed directly to the epidemic through multiple pathways: physical dependence in patients who intended only short-term use, dose escalation driven by tolerance, prescription diversion, and transition to illicit opioids when prescriptions are discontinued.

The human toll has been staggering. The CDC’s 2022 clinical practice guideline was developed in direct response to this crisis. Its core recommendation — that non-opioid therapy is preferred for chronic musculoskeletal pain — reflects the medical community’s recognition that the widespread use of opioids for conditions like myofascial pain has caused far more harm than benefit at a population level.

Substantial

Share of pain clinic patients may have trigger points (estimated)

1-4 Weeks

Until tolerance requires dose escalation

5-7 Days

Until physical dependence can develop

§ 05

What the Guidelines Say

Every major clinical practice guideline for chronic pain converges on the same conclusion: opioids are not recommended for chronic musculoskeletal pain including myofascial pain syndrome.

CDC Clinical Practice Guideline (2022)

StrongNon-opioid therapies are preferred for chronic pain. When opioids are used, they should be combined with non-pharmacologic and non-opioid pharmacologic therapies. Clinicians should prescribe the lowest effective dose of immediate-release opioids. For chronic musculoskeletal pain, the guideline explicitly prioritizes physical therapy, exercise, cognitive behavioral therapy, NSAIDs, and specific antidepressants over opioids.

VA/DoD Clinical Practice Guideline (2022)

Strong AgainstStrong recommendation AGAINST initiation of long-term opioid therapy for chronic non-cancer pain. For patients already on long-term opioid therapy, the guideline recommends a shared decision-making approach to tapering toward the lowest effective dose or discontinuation when risks outweigh benefits.

AAPM/APS Guidelines (2009)

Moderate AgainstOpioids should not be considered first-line therapy for chronic non-cancer pain. Before initiating opioid therapy, clinicians should conduct a thorough assessment, establish treatment goals, obtain informed consent, and consider risk stratification. Opioids should be continued only if meaningful pain reduction and functional improvement are demonstrated.

International Association for the Study of Pain (IASP)

Multimodal PreferredRecommends a multimodal approach for myofascial pain syndrome that prioritizes physical therapies (manual therapy, exercise, dry needling), psychological approaches (CBT, pain neuroscience education), and targeted pharmacotherapy (topical agents, muscle relaxants). Opioids are not listed among recommended treatments for myofascial pain.

Travell & Simons (Myofascial Pain and Dysfunction)

Not RecommendedThe definitive textbook on myofascial trigger point diagnosis and treatment by Janet Travell and David Simons makes no recommendation for opioid use in trigger point management. The recommended treatments are specific stretching techniques, trigger point injection (with local anesthetic or dry needling), spray-and-stretch, manual pressure release, and correction of perpetuating factors. Systemic opioids are conspicuously absent from the treatment framework.

§ 06

Common Opioids — Quick Reference

Tramadol

Weak Opioid + SNRIModerate RiskPotency: Low

MechanismDual mechanism: weak mu-opioid receptor agonist combined with serotonin-norepinephrine reuptake inhibition. The O-desmethyltramadol metabolite (M1) has 200x greater affinity for mu-receptors than the parent compound.

Relevance to myofascial painOften prescribed as a "safer" alternative, but still carries opioid risks including dependence and tolerance. The SNRI component may provide some independent benefit for chronic pain but does not address trigger point pathology. Additional risks include seizures (especially with TCAs, SSRIs, or MAOIs), serotonin syndrome, and hypoglycemia.

Codeine

Weak Opioid (Prodrug)Moderate RiskPotency: Very Low

MechanismProdrug requiring hepatic CYP2D6 conversion to morphine for analgesic effect. Only 5-10% of codeine is converted to morphine in most individuals. Genetic polymorphisms in CYP2D6 cause extreme variability.

Relevance to myofascial painHighly unpredictable efficacy due to CYP2D6 genetic variability. Poor metabolizers (5-10% of Caucasians) get no analgesic benefit. Ultra-rapid metabolizers (1-2% of Caucasians, up to 29% of some African populations) may experience dangerously high morphine levels. This pharmacogenomic variability makes codeine a particularly poor choice for chronic musculoskeletal conditions like Myofascial Pain Syndrome.

Hydrocodone

Semi-Synthetic OpioidHigh RiskPotency: Moderate

MechanismMu-opioid receptor agonist with some kappa-receptor activity. Partially metabolized by CYP2D6 to the more potent hydromorphone. Available only in combination products (with acetaminophen or ibuprofen) in most countries.

Relevance to myofascial painOne of the most commonly prescribed opioids in the United States and a major contributor to the opioid epidemic. High abuse and diversion potential. The combination formulations add hepatotoxicity risk (acetaminophen) or GI bleeding risk (ibuprofen) on top of opioid risks. Inappropriate for chronic myofascial pain management.

Oxycodone

Semi-Synthetic OpioidVery High RiskPotency: High

MechanismPotent mu-opioid receptor agonist with additional kappa-receptor activity. Well-absorbed orally with 60-87% bioavailability. Extended-release formulations (OxyContin) were a major driver of the opioid epidemic.

Relevance to myofascial painHigh abuse potential. Extended-release formulations were specifically marketed for chronic non-cancer pain — a practice now widely recognized as having contributed to the opioid crisis. There is no evidence supporting oxycodone for myofascial trigger point pain, and the risk-benefit ratio is strongly negative.

Fentanyl

Synthetic OpioidExtreme RiskPotency: Extreme

MechanismHighly selective mu-opioid receptor agonist. 50-100 times more potent than morphine. Highly lipophilic with rapid onset of action. Available as transdermal patches, lozenges, sublingual tablets, nasal sprays, and intravenous formulations.

Relevance to myofascial painAbsolutely inappropriate for myofascial pain syndrome. The potency carries extreme overdose risk. Fentanyl is specifically documented to cause chest wall rigidity and generalized skeletal muscle rigidity — directly worsening the muscle tension that defines trigger point pathology. Reserved only for severe cancer pain and palliative care in opioid-tolerant patients.

Morphine

Natural Opioid AlkaloidHigh RiskPotency: Moderate-High

MechanismThe prototypical opioid against which all others are compared. Full mu-opioid receptor agonist with lower affinity for kappa and delta receptors. Glucuronidated in the liver to morphine-3-glucuronide (neuroexcitatory, no analgesia) and morphine-6-glucuronide (potent analgesic, renally cleared).

Relevance to myofascial painThe reference standard opioid, but it has no role in the treatment of myofascial trigger point pain. Its use is appropriate for acute surgical pain, severe trauma, and cancer-related pain. Prescribing morphine for chronic myofascial pain exposes patients to all the risks of opioid therapy — tolerance, dependence, hyperalgesia, sedation, constipation, respiratory depression — without addressing the mechanical pathology.

§ 07

What Works Instead

Effective, evidence-based treatments for myofascial trigger points exist at every level of severity and complexity. Unlike opioids, these interventions address the actual pathology — the contracted sarcomeres, the dysfunctional motor endplates, the local inflammation, and the perpetuating factors that maintain the trigger point cycle.

Tier 1 — First-Line

Physical & mechanical interventions

Physical Therapy & Targeted Exercise — Addresses the mechanical dysfunction directly. Stretching elongates shortened sarcomeres, eccentric strengthening restores normal muscle function, and postural correction eliminates the biomechanical perpetuating factors that maintain trigger points. Evidence supports PT as the foundation of myofascial pain treatment.
Stretching Programs — Sustained passive stretching of the affected muscle group lengthens the contracted taut band, restores full range of motion, and reduces the compressive load on intramuscular blood vessels. Spray-and-stretch (using vapocoolant spray followed by passive stretching) is the original Travell technique for trigger point deactivation.
Dry Needling — Directly targets the trigger point by inserting a thin filiform needle into the taut band to elicit a local twitch response (LTR). This disrupts the dysfunctional motor endplate, breaks the sarcomere contraction cycle, and normalizes the local biochemical environment. Strong evidence base with multiple systematic reviews and meta-analyses supporting its efficacy.
Self-Massage & Myofascial Release — Mechanical compression of the trigger point increases local blood flow, reduces ischemia, provides a neurophysiological stretch stimulus, and may disrupt contracted sarcomeres. Foam rolling, lacrosse ball release, and manual self-compression are accessible, zero-cost interventions that patients can perform daily.

Tier 2 — Topical & Oral Pharmacotherapy

Non-opioid medications

NSAIDs (Ibuprofen, Naproxen, Diclofenac) — Unlike opioids, NSAIDs directly reduce the prostaglandin-mediated inflammation and peripheral sensitization at the trigger point. Topical NSAIDs (diclofenac gel) provide local anti-inflammatory action with minimal systemic exposure. Evidence supports short-term use for myofascial pain flares.
Topical Lidocaine (Patches/Cream) — Provides sodium channel blockade at the peripheral nociceptor level, reducing pain signal generation directly at the trigger point. Lidocaine 5% patches can be applied over trigger point regions for up to 12 hours with minimal systemic absorption.
Topical Capsaicin — Depletes substance P from peripheral C-fiber nociceptors through TRPV1 receptor activation. With repeated application, produces desensitization of pain fibers in the trigger point region. The 8% capsaicin patch (Qutenza) provides 3 months of benefit from a single application.
Muscle Relaxants (Tizanidine, Cyclobenzaprine) — Reduce muscle tone through distinct mechanisms. Tizanidine is a central alpha-2 adrenergic agonist that reduces spinal motor neuron excitability. Cyclobenzaprine is structurally related to tricyclic antidepressants and reduces muscle spasm via brainstem pathways. Both directly address the excessive muscle contraction component of trigger points.

Tier 3 — Central-Acting Non-Opioid Medications

Antidepressants & neuromodulators

TCAs (Amitriptyline, Nortriptyline) — Low-dose tricyclic antidepressants (10-50 mg nightly) provide multimodal analgesia: serotonin and norepinephrine reuptake inhibition enhances descending pain modulation, sodium channel blockade provides peripheral analgesic effects, and NMDA receptor antagonism may counteract central sensitization. Also improves sleep quality, which is a critical perpetuating factor for myofascial pain.
SNRIs (Duloxetine, Milnacipran) — Duloxetine (Cymbalta) has FDA approval for chronic musculoskeletal pain. It enhances descending serotonergic and noradrenergic pain inhibition at the spinal cord level. Unlike opioids, it does not cause tolerance, dependence, or hyperalgesia. Milnacipran (Savella) is FDA-approved for fibromyalgia and may benefit patients with overlapping myofascial pain and fibromyalgia.
Gabapentinoids (Gabapentin, Pregabalin) — Bind to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release in the dorsal horn. May be beneficial when trigger point pain has developed a neuropathic component (central sensitization, allodynia, hyperalgesia). Most useful as adjuncts when myofascial pain has become chronic with central sensitization.

Tier 4 — Advanced Interventions

For refractory trigger points

Trigger Point Injections — Injection of local anesthetic (lidocaine, bupivacaine) directly into the trigger point provides immediate pain relief while the needle itself mechanically disrupts the taut band — the same mechanism as dry needling, enhanced by the pharmacological effect of the anesthetic on sodium channels at the motor endplate.
Botulinum Toxin (BOTOX) — Blocks acetylcholine release at the motor endplate — directly addressing the fundamental mechanism of trigger point formation. SNARE protein cleavage provides 3-6 months of effect. Additionally inhibits release of pain neurotransmitters (substance P, CGRP, glutamate) from sensory nerve terminals. Reserved for refractory trigger points unresponsive to conservative treatment.
Extracorporeal Shockwave Therapy (ESWT) — Acoustic pressure waves create mechanical stress at the trigger point, disrupting contracted sarcomeres, increasing local blood flow through neovascularization, and modulating pain signaling. Non-invasive with a growing evidence base — small RCTs and systematic reviews report meaningful pain reduction and pressure-pain-threshold improvement, though effect sizes vary widely between studies. No medication-related side effects.

§ 08

If You're Currently on Opioids for myofascial pain

Do NOT Stop Abruptly

Abrupt opioid cessation after chronic use can cause severe withdrawal syndrome: severe myalgias, diaphoresis, insomnia, anxiety, tachycardia, hypertension, nausea, vomiting, and diarrhea. In rare cases, acute withdrawal can be medically dangerous. Always taper under medical supervision.

Consult Your Prescribing Physician

Schedule a dedicated appointment to discuss your desire to taper. Your physician can develop a personalized tapering plan based on your current dose, duration of use, and individual factors. A typical tapering schedule involves reducing the dose by 10-25% every 1 to 4 weeks, though faster or slower tapers may be appropriate depending on circumstances.

Establish Multimodal Treatments First

Before beginning to taper, establish effective non-opioid treatments for your trigger point pain. Begin physical therapy, start a stretching program, consider dry needling or trigger point injections, and initiate any appropriate non-opioid medications. Having these treatments in place before tapering reduces pain recurrence during dose reduction.

Consider a Bridge Medication

Your physician may rotate you to tramadol or a partial agonist like buprenorphine as a bridge during tapering. Adjunct medications such as clonidine (for autonomic withdrawal symptoms), low-dose naltrexone, and sleep aids can ease the transition. Non-opioid analgesics (NSAIDs, acetaminophen) should be maximized.

Address Pain Psychology

Cognitive behavioral therapy for chronic pain (CBT-CP) is one of the most effective interventions for patients tapering opioids. Pain neuroscience education helps patients understand the neurobiological basis of chronic pain and the role of central sensitization. Acceptance and Commitment Therapy (ACT) and mindfulness-based stress reduction (MBSR) also have evidence for chronic pain management during opioid tapering.

Use Your Care Team and OUD Treatment

Opioid tapering can be physically and psychologically challenging. Communicate openly with your healthcare team, consider support groups for chronic pain, and engage family or friends in your plan. If you are struggling with opioid use disorder, your physician can discuss medication-assisted treatment with buprenorphine or naltrexone.

Key Takeaways

Myofascial trigger point pain is a peripheral, mechanical disorder — opioids are central-acting medications that do not address the underlying contracture, motor endplate dysfunction, or local biochemical milieu.
Major medical guidelines (CDC, VA/DoD, AAPM, IASP) specifically recommend against opioids for chronic musculoskeletal pain including myofascial pain. Opioids are not part of any evidence-based trigger point treatment protocol.
Opioid-induced hyperalgesia can paradoxically worsen pain sensitivity over time, making trigger points more painful, not less — the opposite of the intended therapeutic effect.
Opioids reduce physical activity, promote sedation, and can increase muscle rigidity — all of which worsen trigger points and undermine the treatments (stretching, exercise, PT) that actually help.
Effective, evidence-based alternatives exist at every level of severity: physical therapy and dry needling for first-line treatment, targeted medications (NSAIDs, muscle relaxants, TCAs, SNRIs) for pharmacologic support, and advanced interventions (trigger point injections, BOTOX, shockwave) for refractory cases.
If you are currently taking opioids for myofascial pain, do not stop abruptly — work with your physician to develop a supervised tapering plan while establishing effective multimodal treatments.

The bottom line:Myofascial trigger point pain is highly treatable with evidence-based interventions that directly address the underlying pathology. Opioids are not among those interventions. If you are living with myofascial pain, effective treatment options exist — and none of them require opioids.

Opioids Are Not Recommended for Myofascial Pain

Opioids do not address the underlying trigger point pathology, carry high risks of dependence, tolerance, and opioid-induced hyperalgesia, and can paradoxically worsen chronic pain. Evidence-based alternatives (trigger point injections, dry needling, physical therapy, NSAIDs, muscle relaxants) are safer and more effective.